Key result
Intracoronary N-acetylcysteine boosts acetylcholine-mediated coronary blood flow by ~36% and enhances epicardial vasodilation.
Why the study?
Coronary atherosclerosis is associated with endothelial dysfunction and reduced nitric oxide activity, and it was uncertain whether N-acetylcysteine improves endothelium-dependent vasomotion.
Does intracoronary and intraarterial N-acetylcysteine improve coronary and peripheral endothelium-dependent vasodilation in patients undergoing cardiac catheterization?
Does intracoronary and intraarterial N-acetylcysteine improve coronary and peripheral endothelium-dependent vasodilation in patients undergoing cardiac catheterization?
Thiol supplementation with N-acetylcysteine improves human coronary and peripheral endothelium-dependent vasodilation, highlighting the role of the redox state in regulating vascular function.
Answers are grounded in this paper and cite their sources.
Does not support clinical NAC use; leaves open its role in vascular function trials.
Objectives We investigated whether N-acetylcysteine (NAC), a reduced thiol that modulates redox state and forms adducts of nitric oxide (NO), improves endothelium-dependent vasomotion. Background Coronary atherosclerosis is associated with endothelial dysfunction and reduced NO activity. Methods In 16 patients undergoing cardiac catheterization, seven with and nine without atherosclerosis, we assessed endothelium-dependent vasodilation with acetylcholine (ACH) and endothelium-independent vasodilation with nitroglycerin (NTG) and sodium nitroprusside (SNP) before and after intracoronary NAC. In 14 patients femoral vascular responses to ACH, NTG and SNP were measured before and after NAC. Results Intraarterial NAC did not change resting coronary or peripheral vascular tone. N-acetylcysteine potentiated ACH-mediated coronary vasodilation; coronary blood flow was 36 +/- 11% higher (p < 0.02), and epicardial diameter changed from -1.2 +/- 2% constriction to 4.7 +/- 2% dilation after NAC (p = 0.03). Acetylcholine-mediated femoral vasodilation was similarly potentiated by NAC (p = 0.001). Augmentation of the ACH response was similar in patients with or without atherosclerosis. N-acetylcysteine did not affect NTG-mediated vasodilation in either the femoral or coronary circulations and did not alter SNP responses in the femoral circulation. In contrast, coronary vasodilation with SNP was significantly greater after NAC (p < 0.05). Conclusions Thiol supplementation with NAC improves human coronary and peripheral endothelium-dependent vasodilation. Nitroglycerin responses are not enhanced, but SNP-mediated responses are potentiated only in the coronary circulation. These NO-enhancing effects of thiols reflect the importance of the redox state in the control of vascular function and may be of therapeutic benefit in treating acute and chronic manifestations of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Andrews et al. (2001) studied Coronary atherosclerosis (n=16). Intracoronary/intraarterial N-acetylcysteine (NAC) vs. Baseline (pre-NAC vascular response to acetylcholine, nitroglycerin, and sodium nitroprusside) was evaluated on Acetylcholine-mediated coronary epicardial diameter change (p=0.03). Intracoronary N-acetylcysteine potentiated acetylcholine-mediated coronary blood flow by 36% (p<0.02) and epicardial dilation from -1.2% to 4.7% (p=0.03).
Synapse has enriched 10 related papers. Consider them for comparative context: